Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2010, Article ID 219583, 10 pages
http://dx.doi.org/10.1155/2010/219583
Review Article

Inflammatory Mediators and Insulin Resistance in Obesity: Role of Nuclear Receptor Signaling in Macrophages

Department of Regenerative Cardiology, Centro Nacional de Investigaciones Cardiovasculares, Instituto de Salud Carlos III, C/Melchor Fernández Almagro 3, 28029 Madrid, Spain

Received 4 December 2009; Accepted 16 March 2010

Academic Editor: Giamila Fantuzzi

Copyright © 2010 Lucía Fuentes et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. R. Greenfield and L. V. Campbell, “Relationship between inflammation, insulin resistance and type 2 diabetes: ‘cause or effect’?” Current Diabetes Reviews, vol. 2, no. 2, pp. 195–211, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. L. A. Ahmed, R. M. Joakimsen, G. K. Berntsen, V. Fonnebo, and H. Schirmer, “Diabetes mellitus and the risk of non-vertebral fractures: the Tromso study,” Osteoporosis International, vol. 17, no. 4, pp. 495–500, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Jaskiewicz, R. Rzepko, and Z. Sledzinski, “Fibrogenesis in fatty liver associated with obesity and diabetes mellitus type 2,” Digestive Diseases and Sciences, vol. 53, no. 3, pp. 785–788, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. K.-H. Mak, S. Ma, D. Heng et al., “Impact of sex, metabolic syndrome, and diabetes mellitus on cardiovascular events,” American Journal of Cardiology, vol. 100, no. 2, pp. 227–233, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. O. Hamdy, S. Porramatikul, and E. Al-Ozairi, “Metabolic obesity: the paradox between visceral and subcutaneous fat,” Current Diabetes Reviews, vol. 2, no. 4, pp. 367–373, 2006. View at Google Scholar · View at Scopus
  6. L. Henkin, R. N. Bergman, D. W. Bowden et al., “Genetic epidemiology of insulin resistance and visceral adiposity: the IRAS Family Study design and methods,” Annals of Epidemiology, vol. 13, no. 4, pp. 211–217, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. D. E. Chiriboga, Y. Ma, W. Li et al., “Gender differences in predictors of body weight and body weight change in healthy adults,” Obesity, vol. 16, no. 1, pp. 137–145, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. B. Thorand, J. Baumert, H. Kolb et al., “Sex differences in the prediction of type 2 diabetes by inflammatory markers: results from the MONICA/KORA Augsburg case-cohort study, 1984–2002,” Diabetes Care, vol. 30, no. 4, pp. 854–860, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. S. C. Woods, K. Gotoh, and D. J. Clegg, “Gender differences in the control of energy homeostasis,” Experimental Biology and Medicine, vol. 228, no. 10, pp. 1175–1180, 2003. View at Google Scholar · View at Scopus
  10. F. Assimacopoulos-Jeannet, “Fat storage in pancreas and in insulin-sensitive tissues in pathogenesis of type 2 diabetes,” International Journal of Obesity, vol. 28, supplement 4, pp. S53–S57, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Heikkinen, J. Auwerx, and C. A. Argmann, “PPARγ in human and mouse physiology,” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 999–1013, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. J. M. Weinberg, “Lipotoxicity,” Kidney International, vol. 70, no. 9, pp. 1560–1566, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. S. E. Shoelson, J. Lee, and A. B. Goldfine, “Inflammation and insulin resistance,” Journal of Clinical Investigation, vol. 116, no. 7, pp. 1793–1801, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. S. P. Weisberg, D. McCann, M. Desai, M. Rosenbaum, R. L. Leibel, and A. W. Ferrante Jr., “Obesity is associated with macrophage accumulation in adipose tissue,” Journal of Clinical Investigation, vol. 112, no. 12, pp. 1796–1808, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. G. S. Hotamisligil, “Inflammation and metabolic disorders,” Nature, vol. 444, no. 7121, pp. 860–867, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. C. K. Glass and M. G. Rosenfeld, “The coregulator exchange in transcriptional functions of nuclear receptors,” Genes and Development, vol. 14, no. 2, pp. 121–141, 2000. View at Google Scholar · View at Scopus
  17. P. Delerive, K. De Bosscher, S. Besnard et al., “Peroxisome proliferator-activated receptor a negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-?B and AP-1,” Journal of Biological Chemistry, vol. 274, no. 45, pp. 32048–32054, 1999. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation,” Nature, vol. 391, no. 6662, pp. 79–82, 1998. View at Publisher · View at Google Scholar · View at Scopus
  19. F. Grun and B. Blumberg, “Minireview: the case for obesogens,” Molecular Endocrinology, vol. 23, no. 8, pp. 1127–1134, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Mantovani, A. Sica, S. Sozzani, P. Allavena, A. Vecchi, and M. Locati, “The chemokine system in diverse forms of macrophage activation and polarization,” Trends in Immunology, vol. 25, no. 12, pp. 677–686, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Mantovani, S. Sozzani, M. Locati, P. Allavena, and A. Sica, “Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes,” Trends in Immunology, vol. 23, no. 11, pp. 549–555, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. S. P. Weisberg, D. Hunter, R. Huber et al., “CCR2 modulates inflammatory and metabolic effects of high-fat feeding,” Journal of Clinical Investigation, vol. 116, no. 1, pp. 115–124, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. D. K. Brake, E. O. Smith, H. Mersmann, C. W. Smith, and R. L. Robker, “ICAM-1 expression in adipose tissue: effects of diet-induced obesity in mice,” American Journal of Physiology, vol. 291, pp. C1232–C1239, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Patsouris, P.-P. Li, D. Thapar, J. Chapman, J. M. Olefsky, and J. G. Neels, “Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals,” Cell Metabolism, vol. 8, no. 4, pp. 301–309, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Fujisaka, I. Usui, A. Bukhari et al., “Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice,” Diabetes, vol. 58, no. 11, pp. 2574–2582, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. C. N. Lumeng, S. M. DeYoung, J. L. Bodzin, and A. R. Saltiel, “Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity,” Diabetes, vol. 56, no. 1, pp. 16–23, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Tsuchiya, H. Sakai, N. Suzuki et al., “Chronic blockade of nitric oxide synthesis reduces adiposity and improves insulin resistance in high fat-induced obese mice,” Endocrinology, vol. 148, no. 10, pp. 4548–4556, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. C. N. Lumeng, J. L. Bodzin, and A. R. Saltiel, “Obesity induces a phenotypic switch in adipose tissue macrophage polarization,” Journal of Clinical Investigation, vol. 117, no. 1, pp. 175–184, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. F. Geissmann, S. Jung, and D. R. Littman, “Blood monocytes consist of two principal subsets with distinct migratory properties,” Immunity, vol. 19, no. 1, pp. 71–82, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. F. K. Swirski, P. Libby, E. Aikawa et al., “Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata,” Journal of Clinical Investigation, vol. 117, no. 1, pp. 195–205, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Ghanim, A. Aljada, D. Hofmeyer, T. Syed, P. Mohanty, and P. Dandona, “Circulating mononuclear cells in the obese are in a proinflammatory state,” Circulation, vol. 110, no. 12, pp. 1564–1571, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. R. D. Stout, C. Jiang, B. Matta, I. Tietzel, S. K. Watkins, and J. Suttles, “Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences,” Journal of Immunology, vol. 175, no. 1, pp. 342–349, 2005. View at Google Scholar · View at Scopus
  33. S. K. Watkins, N. K. Egilmez, J. Suttles, and R. D. Stout, “IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo,” Journal of Immunology, vol. 178, no. 3, pp. 1357–1362, 2007. View at Google Scholar · View at Scopus
  34. J. I. Odegaard, R. R. Ricardo-Gonzalez, M. H. Goforth et al., “Macrophage-specific PPAR? controls alternative activation and improves insulin resistance,” Nature, vol. 447, no. 7148, pp. 1116–1120, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. J. I. Odegaard, R. R. Ricardo-Gonzalez, E. A. Red et al., “Alternative M2 activation of Kupffer cells by PPARd ameliorates obesity-induced insulin resistance,” Cell Metabolism, vol. 7, no. 6, pp. 496–507, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. T. You and B. J. Nicklas, “Chronic inflammation: role of adipose tissue and modulation by weight loss,” Current Diabetes Reviews, vol. 2, no. 1, pp. 29–37, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Stenholm, A. Koster, D. E. Alley et al., “Adipocytokines and the metabolic syndrome among older persons with and without obesity—the InCHIANTI Study,” Clinical Endocrinology. In press. View at Publisher · View at Google Scholar
  38. X. J. Sun and F. Liu, “Phosphorylation of IRS proteins. Yin-Yang regulation of insulin signaling,” Vitamins and Hormones, vol. 80, pp. 351–387, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. L. F. del Aguila, K. P. Claffey, and J. P. Kirwan, “TNF-α impairs insulin signaling and insulin stimulation of glucose uptake in C2C12 muscle cells,” American Journal of Physiology, vol. 276, no. 5, pp. E849–E855, 1999. View at Google Scholar · View at Scopus
  40. I. Nieto-Vazquez, S. Fernandez-Veledo, D. K. Kramer, R. Vila-Bedmar, L. Garcia-Guerra, and M. Lorenzo, “Insulin resistance associated to obesity: the link TNF-alpha,” Archives of Physiology and Biochemistry, vol. 114, no. 3, pp. 183–194, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. P. O. Prada, H. G. Zecchin, A. L. Gasparetti et al., “Western diet modulates insulin signaling, c-jun N-terminal kinase activity, and insulin receptor substrate-1ser307 phosphorylation in a tissue-specific fashion,” Endocrinology, vol. 146, no. 3, pp. 1576–1587, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Yuan, N. Konstantopoulos, J. Lee et al., “Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkß,” Science, vol. 293, no. 5535, pp. 1673–1677, 2001. View at Publisher · View at Google Scholar · View at Scopus
  43. L. Rui, M. Yuan, D. Frantz, S. Shoelson, and M. F. White, “SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2,” Journal of Biological Chemistry, vol. 277, no. 44, pp. 42394–42398, 2002. View at Publisher · View at Google Scholar · View at Scopus
  44. B. T. Kile, B. A. Schulman, W. S. Alexander, N. A. Nicola, H. M. E. Martin, and D. J. Hilton, “The SOCS box: a tale of destruction and degradation,” Trends in Biochemical Sciences, vol. 27, no. 5, pp. 235–241, 2002. View at Publisher · View at Google Scholar · View at Scopus
  45. C. Jiang, A. T. Ting, and B. Seed, “PPAR-γ agonists inhibit production of monocyte inflammatory cytokines,” Nature, vol. 391, no. 6662, pp. 82–86, 1998. View at Publisher · View at Google Scholar · View at Scopus
  46. H. Shu, B. Wong, G. Zhou et al., “Activation of PPARa or ? reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells,” Biochemical and Biophysical Research Communications, vol. 267, no. 1, pp. 345–349, 2000. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Castrillo, S. B. Joseph, C. Marathe, D. J. Mangelsdorf, and P. Tontonoz, “Liver X receptor-dependent repression of matrix metalloproteinase-9 expression in macrophages,” Journal of Biological Chemistry, vol. 278, no. 12, pp. 10443–10449, 2003. View at Publisher · View at Google Scholar · View at Scopus
  48. S. B. Joseph, A. Castrillo, B. A. Laffitte, D. J. Mangelsdorf, and P. Tontonoz, “Reciprocal regulation of inflammation and lipid metabolism by liver X receptors,” Nature Medicine, vol. 9, no. 2, pp. 213–219, 2003. View at Publisher · View at Google Scholar · View at Scopus
  49. B. P. Neve, D. Corseaux, G. Chinetti et al., “PPARa agonists inhibit tissue factor expression in human monocytes and macrophages,” Circulation, vol. 103, no. 2, pp. 207–212, 2001. View at Google Scholar · View at Scopus
  50. C.-H. Lee, A. Chawla, N. Urbiztondo et al., “Transcriptional repression of atherogenic inflammation: modulation by PPARd,” Science, vol. 302, no. 5644, pp. 453–457, 2003. View at Publisher · View at Google Scholar · View at Scopus
  51. A. L. Hevener, J. M. Olefsky, D. Reichart et al., “Macrophage PPAR? is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones,” Journal of Clinical Investigation, vol. 117, no. 6, pp. 1658–1669, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Ghisletti, W. Huang, S. Ogawa et al., “Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPAR?,” Molecular Cell, vol. 25, no. 1, pp. 57–70, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. K. Clement, N. Viguerie, C. Poitou et al., “Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects,” FASEB Journal, vol. 18, no. 14, pp. 1657–1669, 2004. View at Publisher · View at Google Scholar · View at Scopus
  54. A. H. Berg, T. P. Combs, and P. E. Scherer, “ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism,” Trends in Endocrinology and Metabolism, vol. 13, no. 2, pp. 84–89, 2002. View at Publisher · View at Google Scholar · View at Scopus
  55. Z. Punthakee, E. E. Delvin, J. O'Loughlin et al., “Adiponectin, adiposity, and insulin resistance in children and adolescents,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 6, pp. 2119–2125, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. Y. Arita, S. Kihara, N. Ouchi et al., “Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity,” Biochemical and Biophysical Research Communications, vol. 257, no. 1, pp. 79–83, 1999. View at Publisher · View at Google Scholar · View at Scopus
  57. C. Fernandes-Santos, R. E. Carneiro, L. de Souza Mendonca, M. B. Aguila, and C. A. Mandarim-de-Lacerda, “Pan-PPAR agonist beneficial effects in overweight mice fed a high-fat high-sucrose diet,” Nutrition, vol. 25, no. 7-8, pp. 818–827, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. S. Lemieux, J. P. Despres, S. Moorjani et al., “Are gender differences in cardiovascular disease risk factors explained by the level of visceral adipose tissue?” Diabetologia, vol. 37, no. 8, pp. 757–764, 1994. View at Google Scholar · View at Scopus
  59. F. Lonnqvist, A. Thorne, V. Large, and P. Arner, “Sex differences in visceral fat lipolysis and metabolic complications of obesity,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, no. 7, pp. 1472–1480, 1997. View at Google Scholar · View at Scopus
  60. G. Zappala and M. M. Rechler, “IGFBP-3, hypoxia and TNF-α inhibit adiponectin transcription,” Biochemical and Biophysical Research Communications, vol. 382, no. 4, pp. 785–789, 2009. View at Publisher · View at Google Scholar · View at Scopus
  61. H. Huang, P.-H. Park, M. R. McMullen, and L. E. Nagy, “Mechanisms for the anti-inflammatory effects of adiponectin in macrophages,” Journal of Gastroenterology and Hepatology, vol. 23, supplement 1, pp. S50–S53, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. N. Maeda, M. Takahashi, T. Funahashi et al., “PPAR? ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein,” Diabetes, vol. 50, no. 9, pp. 2094–2099, 2001. View at Google Scholar · View at Scopus
  63. J.-F. Landrier, E. Gouranton, C. El Yazidi et al., “Adiponectin expression is induced by vitamin E via a peroxisome proliferator-activated receptor ?-dependent mechanism,” Endocrinology, vol. 150, no. 12, pp. 5318–5325, 2009. View at Publisher · View at Google Scholar · View at Scopus
  64. X. Rong, Y. Li, K. Ebihara et al., “An adipose tissue-independent insulin-sensitizing action of telmisartan: a study in lipodystrophic mice,” Journal of Pharmacology and Experimental Therapeutics, vol. 331, no. 3, pp. 1096–1103, 2009. View at Publisher · View at Google Scholar · View at Scopus
  65. I. A. Leclercq, M. A. Da Silva, B. Schroyen, N. Van Hul, and A. Geerts, “Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences,” Journal of Hepatology, vol. 47, no. 1, pp. 142–156, 2007. View at Publisher · View at Google Scholar · View at Scopus
  66. M. Bilzer, F. Roggel, and A. L. Gerbes, “Role of Kupffer cells in host defense and liver disease,” Liver International, vol. 26, no. 10, pp. 1175–1186, 2006. View at Publisher · View at Google Scholar · View at Scopus
  67. D. Zhang, M. Sun, D. Samols, and I. Kushner, “STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6,” Journal of Biological Chemistry, vol. 271, no. 16, pp. 9503–9509, 1996. View at Publisher · View at Google Scholar · View at Scopus
  68. Y. Kamada, S. Tamura, S. Kiso et al., “Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin,” Gastroenterology, vol. 125, no. 6, pp. 1796–1807, 2003. View at Publisher · View at Google Scholar · View at Scopus
  69. E. C. Sleyster and D. L. Knook, “Relation between localization and function of rat liver Kupffer cells,” Laboratory Investigation, vol. 47, no. 5, pp. 484–490, 1982. View at Google Scholar · View at Scopus
  70. D. L. Laskin, B. Weinberger, and J. D. Laskin, “Functional heterogeneity in liver and lung macrophages,” Journal of Leukocyte Biology, vol. 70, no. 2, pp. 163–170, 2001. View at Google Scholar
  71. J. H. Lefkowitch, J. H. Haythe, and N. Regent, “Kupffer cell aggregation and perivenular distribution in steatohepatitis,” Modern Pathology, vol. 15, no. 7, pp. 699–704, 2002. View at Publisher · View at Google Scholar · View at Scopus
  72. M. Guebre-Xabier, S. Yang, H. Z. Lin, R. Schwenk, U. Krzych, and A. M. Diehl, “Altered hepatic lymphocyte subpopulations in obesity-related murine fatty livers: potential mechanism for sensitization to liver damage,” Hepatology, vol. 31, no. 3, pp. 633–640, 2000. View at Google Scholar · View at Scopus
  73. M. Kremer, I. N. Hines, R. J. Milton, and M. D. Wheeler, “Favored T helper 1 response in a mouse model of hepatosteatosis is associated with enhanced T cell-mediated hepatitis,” Hepatology, vol. 44, no. 1, pp. 216–227, 2006. View at Publisher · View at Google Scholar · View at Scopus
  74. A. M. Neyrinck, P. D. Cani, E. M. Dewulf, F. De Backer, L. B. Bindels, and N. M. Delzenne, “Critical role of Kupffer cells in the management of diet-induced diabetes and obesity,” Biochemical and Biophysical Research Communications, vol. 385, no. 3, pp. 351–356, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. C. A. Rivera, P. Adegboyega, N. van Rooijen, A. Tagalicud, M. Allman, and M. Wallace, “Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis,” Journal of Hepatology, vol. 47, no. 4, pp. 571–579, 2007. View at Publisher · View at Google Scholar · View at Scopus
  76. N. Enomoto, Y. Takei, S. Yamashima, K. Ikejima, T. Kitamura, and N. Sato, “Protective effect of pioglitazone against endotoxin-induced liver injury through prevention of Kupffer cell sensitization,” Alcoholism—Clinical and Experimental Research, vol. 29, pp. 216S–219S, 2005. View at Publisher · View at Google Scholar · View at Scopus
  77. K. Uchimura, M. Nakamuta, M. Enjoji et al., “Activation of retinoic X receptor and peroxisome proliferator-activated receptor-? inhibits nitric oxide and tumor necrosis factor-a production in rat Kupffer cells,” Hepatology, vol. 33, no. 1, pp. 91–99, 2001. View at Publisher · View at Google Scholar · View at Scopus
  78. W. Huang, A. Metlakunta, N. Dedousis et al., “Depletion of liver Kupffer cells prevents the development of diet-induced hepatic steatosis and insulin resistance,” Diabetes, vol. 59, no. 2, pp. 347–357, 2010. View at Google Scholar · View at Scopus
  79. R. Stienstra, F. Saudale, C. Duval et al., “Kupffer cells promote hepatic steatosis via interleukin-1ß-dependent suppression of peroxisome proliferator-activated receptor a activity,” Hepatology, vol. 51, no. 2, pp. 511–522, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. C. G. Woods, O. Kosyk, B. U. Bradford et al., “Time course investigation of PPARa- and Kupffer cell-dependent effects of WY-14,643 in mouse liver using microarray gene expression,” Toxicology and Applied Pharmacology, vol. 225, no. 3, pp. 267–277, 2007. View at Publisher · View at Google Scholar · View at Scopus
  81. Z. Punthakee, L. J. Scully, M. M. Guindi, and T. C. Ooi, “Liver fibrosis attributed to lipid lowering medications: two cases,” Journal of Internal Medicine, vol. 250, no. 3, pp. 249–254, 2001. View at Publisher · View at Google Scholar · View at Scopus
  82. M. Uno, S. Kurita, H. Misu et al., “Tranilast, an antifibrogenic agent, ameliorates a dietary rat model of nonalcoholic steatohepatitis,” Hepatology, vol. 48, no. 1, pp. 109–118, 2008. View at Publisher · View at Google Scholar · View at Scopus
  83. F. J. Gonzalez, “The peroxisome proliferator-activated receptor α (PPARα): role in hepatocarcinogenesis,” Molecular and Cellular Endocrinology, vol. 193, no. 1-2, pp. 71–79, 2002. View at Publisher · View at Google Scholar · View at Scopus
  84. K. Kang, S. M. Reilly, V. Karabacak et al., “Adipocyte-derived Th2 cytokines and myeloid PPARd regulate macrophage polarization and insulin sensitivity,” Cell Metabolism, vol. 7, no. 6, pp. 485–495, 2008. View at Publisher · View at Google Scholar · View at Scopus
  85. D. E. Bonds, J. C. Larson, A. V. Schwartz et al., “Risk of fracture in women with type 2 diabetes: the women's health initiative observational study,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 9, pp. 3404–3410, 2006. View at Publisher · View at Google Scholar · View at Scopus
  86. D.-K. Hwang and H.-J. Choi, “The relationship between low bone mass and metabolic syndrome in Korean women,” Osteoporosis International, vol. 21, no. 3, pp. 425–431, 2010. View at Publisher · View at Google Scholar · View at Scopus
  87. A. V. Schwartz and D. E. Sellmeyer, “Women, type 2 diabetes, and fracture risk,” Current Diabetes Reports, vol. 4, no. 5, pp. 364–369, 2004. View at Google Scholar · View at Scopus
  88. P. Vestergaard, “Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis,” Osteoporosis International, vol. 18, no. 4, pp. 427–444, 2007. View at Publisher · View at Google Scholar · View at Scopus
  89. I. R. Reid, “Leptin deficiency—lessons in regional differences in the regulation of bone mass,” Bone, vol. 34, no. 3, pp. 369–371, 2004. View at Publisher · View at Google Scholar · View at Scopus
  90. K. M. Thrailkill, C. K. Lumpkin Jr., R. C. Bunn, S. F. Kemp, and J. L. Fowlkes, “Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues,” American Journal of Physiology, vol. 289, no. 5, pp. E735–E745, 2005. View at Publisher · View at Google Scholar · View at Scopus
  91. Y. Shinoda, M. Yamaguchi, N. Ogata et al., “Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways,” Journal of Cellular Biochemistry, vol. 99, no. 1, pp. 196–208, 2006. View at Publisher · View at Google Scholar · View at Scopus
  92. H. S. Berner, S. P. Lyngstadaas, A. Spahr et al., “Adiponectin and its receptors are expressed in bone-forming cells,” Bone, vol. 35, no. 4, pp. 842–849, 2004. View at Publisher · View at Google Scholar · View at Scopus
  93. K. N. Ealey, J. Kaludjerovic, M. C. Archer, and W. E. Ward, “Adiponectin is a negative regulator of bone mineral and bone strength in growing mice,” Experimental Biology and Medicine, vol. 233, no. 12, pp. 1546–1553, 2008. View at Publisher · View at Google Scholar · View at Scopus
  94. J. B. Richards, A. M. Valdes, K. Burling, U. C. Perks, and T. D. Spector, “Serum adiponectin and bone mineral density in women,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 4, pp. 1517–1523, 2007. View at Publisher · View at Google Scholar · View at Scopus
  95. G. A. Williams, Y. Wang, K. E. Callon et al., “In vitro and in vivo effects of adiponectin on bone,” Endocrinology, vol. 150, no. 8, pp. 3603–3610, 2009. View at Publisher · View at Google Scholar · View at Scopus
  96. G. Schett, S. Kiechl, S. Weger et al., “High-sensitivity C-reactive protein and risk of nontraumatic fractures in the bruneck study,” Archives of Internal Medicine, vol. 166, no. 22, pp. 2495–2501, 2006. View at Publisher · View at Google Scholar · View at Scopus
  97. S. C. Manolagas and R. L. Jilka, “Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis,” New England Journal of Medicine, vol. 332, no. 5, pp. 305–311, 1995. View at Publisher · View at Google Scholar · View at Scopus
  98. W. B. Ershler and E. T. Keller, “Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty,” Annual Review of Medicine, vol. 51, pp. 245–270, 2000. View at Publisher · View at Google Scholar · View at Scopus
  99. M. S. Nanes, “Tumor necrosis factor-α: molecular and cellular mechanisms in skeletal pathology,” Gene, vol. 321, no. 1-2, pp. 1–15, 2003. View at Publisher · View at Google Scholar · View at Scopus
  100. C. Ding, V. Parameswaran, R. Udayan, J. Burgess, and G. Jones, “Circulating levels of inflammatory markers predict change in bone mineral density and resorption in older adults: a longitudinal study,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 5, pp. 1952–1958, 2008. View at Publisher · View at Google Scholar · View at Scopus
  101. M. C. Horowitz and J. A. Lorenzo, “The origins of osteoclasts,” Current Opinion in Rheumatology, vol. 16, no. 4, pp. 464–468, 2004. View at Publisher · View at Google Scholar · View at Scopus
  102. S. C. Manolagas, “Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis,” Endocrine Reviews, vol. 21, no. 2, pp. 115–137, 2000. View at Publisher · View at Google Scholar · View at Scopus
  103. M. Ferron, E. Hinoi, G. Karsenty, and P. Ducy, “Osteocalcin differentially regulates β cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 13, pp. 5266–5270, 2008. View at Publisher · View at Google Scholar · View at Scopus
  104. T. Nomiyama, D. Perez-Tilve, D. Ogawa et al., “Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice,” Journal of Clinical Investigation, vol. 117, no. 10, pp. 2877–2888, 2007. View at Publisher · View at Google Scholar · View at Scopus
  105. N. K. Lee, H. Sowa, E. Hinoi et al., “Endocrine regulation of energy metabolism by the skeleton,” Cell, vol. 130, no. 3, pp. 456–469, 2007. View at Publisher · View at Google Scholar · View at Scopus
  106. A. Grey, “Skeletal consequences of thiazolidinedione therapy,” Osteoporosis International, vol. 19, no. 2, pp. 129–137, 2008. View at Publisher · View at Google Scholar · View at Scopus
  107. S. O. Rzonca, L. J. Suva, D. Gaddy, D. C. Montague, and B. Lecka-Czernik, “Bone is a target for the antidiabetic compound rosiglitazone,” Endocrinology, vol. 145, no. 1, pp. 401–406, 2004. View at Publisher · View at Google Scholar · View at Scopus
  108. Y. Wan, L.-W. Chong, and R. M. Evans, “PPAR-γ regulates osteoclastogenesis in mice,” Nature Medicine, vol. 13, no. 12, pp. 1496–1503, 2007. View at Publisher · View at Google Scholar · View at Scopus
  109. T. Akune, S. Ohba, S. Kamekura et al., “PPAR? insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors,” Journal of Clinical Investigation, vol. 113, no. 6, pp. 846–855, 2004. View at Publisher · View at Google Scholar · View at Scopus
  110. T.-A. Cock, J. Back, F. Elefteriou et al., “Enhanced bone formation in lipodystrophic PPAR?hyp/hyp mice relocates haematopoiesis to the spleen,” EMBO Reports, vol. 5, no. 10, pp. 1007–1012, 2004. View at Publisher · View at Google Scholar · View at Scopus
  111. K. M. Robertson, M. Norgard, S. H. Windahl et al., “Cholesterol-sensing receptors, liver X receptor a and ß, have novel and distinct roles in osteoclast differentiation and activation,” Journal of Bone and Mineral Research, vol. 21, no. 8, pp. 1276–1287, 2006. View at Publisher · View at Google Scholar · View at Scopus
  112. B. Y. Chan, A. Gartland, P. J. M. Wilson et al., “PPAR agonists modulate human osteoclast formation and activity in vitro,” Bone, vol. 40, no. 1, pp. 149–159, 2007. View at Publisher · View at Google Scholar · View at Scopus